Search results
Antibody-Drug Conjugate Picks Up Another Win in HR+/HER2-low Breast Cancer
MedPage Today· 5 days agoThe antibody-drug conjugate (ADC) trastuzumab deruxtecan (T-DXd, Enhertu) significantly improved...
Women denied ‘wonder drug’ that could double terminal breast cancer life expectancy
Daily Telegraph· 4 days agoWomen with HER2-low or ultra-low breast cancer who took Enhertu lived without their cancer growing...
Cancer Drugs: Deals and Licensing for Antibody-Drug Conjugates
The National Law Review· 1 day agoAntibody-drug conjugates (ADCs) are a promising class of cancer treatments with an accelerating...
ASCO 2024: What's New in Breast Cancer Research?
Medscape· 1 day agoDrs Alexandra Thomas and Virginia Kaklamani discuss highlights in breast cancer research from the ASCO 2024 Annual Meeting.
ASCO24: Can Ambrx’s novel ADC break into the metastatic breast cancer market?
Pharmaceutical Technology via Yahoo Finance· 3 days agoARX788 is attempting to enter a crowded field, Enhertu (trastuzumab deruxtecan) is the standard...
AstraZeneca’s breast cancer trial shows ‘unprecedented’ results | Honolulu Star-Advertiser
Honolulu Star-Advertiser· 5 days agoThe findings, presented in Chicago at the annual meeting of the American Society of Clinical...
Breakthroughs in Breast Cancer: Susan G. Komen(R) | Newswise
Newswise· 1 day agoScholars and studies funded by Susan G. Komen(R), the world’s leading breast cancer organization, showcased cutting-edge breast
A drug that prolongs the survival of 67% of patients
Hardwood Paroxysm· 5 days agoFor this reason, the International Breast Cancer Center – Pangea Oncology (IBCC), in Barcelona, has been studying for three years the approach to...
With new Enhertu data, an ADC could overtake chemo in breast cancer
BioPharma Dive via Yahoo Finance· 5 days agoThe findings suggest Enhertu, a type of medicine called an antibody-drug conjugate, should be used...
Small Business - Salisbury Post | Salisbury Post
The Salisbury Post· 5 days agoMEDSIR's PRIMED Study Shows Promising Results for Preventing Sacituzumab Govitecan related Side Effects in the Treatment of HER2-negative Advanced Breast Cancer< ...
